When serious illnesses strike, families face immense emotional and financial distress. Recently, strong observations made by the Supreme Court have brought the murky world of high profit margins on medicines sold through hospital pharmacies into the national spotlight. The court did not mince words, calling the exorbitant pricing of cancer drugs a form of exploitation.
Supreme Court Questions High Margins on Cancer Drugs
During ongoing hearings, a bench comprising Justice Vikram Nath and Justice Sandeep Mehta expressed deep concern over hospitals inflating cancer drug prices by up to ten times. Highlighting specific instances, the court noted how medicines supplied to retailers at around Rs 2,700 were being billed to vulnerable patients at a staggering Rs 27,000.
The bench also questioned the mandatory practice by many private healthcare institutions requiring inpatients to purchase medicines exclusively from the hospital's in-house pharmacy, leaving patients with no viable alternative to shop around for better or fairer rates.
Supreme Court raises serious concerns over high hospital drug margins and pricing practices. #SupremeCourt #Healthcare
— The Freelance (@TheFreelanceIn) September 26, 2023
Regulatory Gaps and the Need for Price Controls
India’s drug pricing mechanism has long divided formulations into scheduled and non-scheduled categories, with the National Pharmaceutical Pricing Authority (NPPA) regulating essential medicines. However, non-scheduled drugs often allow companies substantial freedom in setting initial maximum retail prices (MRPs).
Health advocacy groups, such as the All India Drug Action Network (AIDAN), point out that critical care patients in ICUs or undergoing chemotherapy lack the practical ability to compare prices across pharmacies. While hospitals argue that high operational overheads, cold-chain maintenance, and staffing costs contribute to the final bill, the judiciary's intervention has put the spotlight back on creating a more transparent and equitable pricing structure for life-saving treatments.
'The Freelance' does not independently verify the claims made in videos circulating on social media platforms. This report focuses on ongoing public discussions and judicial observations. Video credits: Respective social media handles/creators.
